Electronic Supplementary Material (ESI) for RSC Advances.

Supporting information

In Vivo Drug Release Behavior and Osseointegration of Doxorubicin-loaded Tissue-engineered Scaffold

Ming Sun[*], *Muwan Chen*[*], *Miao Wang, Jakob Hansen, Anette Baatrup, Frederik Dagnaes-Hansen, Jan Hendrik Duedal Rölfing, Jonas Jensen, Helle Lysdahl, Haisheng Li, Dang Quang Svend Le, Mogens Johannsen, Jørgen Kjems, and Cody E. Bünger*



Figure S1. Release profile and cytotoxicity of DOX from DESCLAYMR scaffold *in vitro.* (A) DOX release concentration from DESCLAYMR scaffolds (ø = 8 mm, h = 10 mm) loaded with DOX (400 μL/scaffold) at 37°C in PBS (pH 7.4) for 7 weeks. Data are presented as mean ± standard deviation. n = 4. (B) Viability of the human osteosarcoma cells MG-63 cultured in DOX release solution from serial timepoints by XTT assay. The DOX release solution from day 35 could inhibit 82% of the osteosarcoma cells.